Products
Sultiam is commercially available in the form of film-coated tablets (Ospolot). It has been approved in many countries since 2003. In Germany, it was approved as early as 1998. In English, it is also referred to as resp.
Structure and properties
Sultiam (C10H14N2O4S2, Mr = 290.4 g/mol) is a sulfonamide derivative that is structurally unrelated to other antiepileptic drugs.
Effects
Sultiam (ATC N03AX03) has anticonvulsant properties. Effects are attributed in part to inhibition of central carbonic anhydrase. Furthermore, sultiam reduces sodium influx into neurons, thereby reducing their excitability.
Indications
For the treatment of Rolando’s epilepsy.
Dosage
According to the professional information. Dose is adjusted on an individual basis. The start of therapy is gradual. Tablets are taken three times daily. Treatment is discontinued gradually.
Contraindications
- Hypersensitivity, including to sulfonamides.
- Renal dysfunction
- Pre-existing psychiatric illness
- Porphyria
- Hyperthyroidism
- Arterial hypertension
- Women of childbearing age and female teenagers older than 12 years of age
- Pregnancy
- Lactation
Full precautions can be found in the drug label.
Interactions
Sultiam is an inhibitor of CYP2C isozymes.
Adverse effects
The most common possible adverse effects include:
- Nausea, vomiting, loss of appetite, weight loss.
- Respiratory disorders
- Hiccups
- Paresthesias in the extremities and face
- Dizziness, headache
- Double vision
- Irritability, fatigue
